However, among patients with <7.7% PD-L1 positivity rate, the rates of seven of eight patients were 0%; thus, it was speculated that tumor without PD-L1 upregulation responding poorly to nivolumab may increase in these patients, whereas PD-L1-expressing cancer cells disappeared until week 8. This evidence concerns the gene CD274 and neoplasm.